单位：[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院外科学系泌尿外科[2]Institute of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院外科学系泌尿外科[3]Translational Medicine Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院转化医学中心党政职能科室科研处[4]Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, USA[5]The Wistar Institute, Philadelphia, Pennsylvania 19104, USA[6]Department of Cell Death and Cancer Genetics, The Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA
Long non-coding RNA (lncRNAs) play a critical role in the development of cancers. LncRNA metastasis-associated lung adenocarcinoma transcript 1(MALAT1) has recently been identified to be involved in tumorigenesis of several cancers such as lung cancer, bladder cancer and so on. Here, we found that MALAT1 exist a higher fold change (Tumor/Normal) in clear cell kidney carcinoma (KIRC) from The Cancer Genome Atlas (TCGA) Data Portal and a negative correlation with miR-200s family. We further demonstrated MALAT1 promote KIRC proliferation and metastasis through sponging miR-200s in vitro and in vivo. In addition, miR-200c can partly reverse the MALAT1's stimulation on proliferation and metastasis in KIRC. In summary we unveil a branch of the MALAT1/miR-200s/ZEB2 pathway that regulates the progression of KIRC. The inhibition of MALAT1 expression may be a promising strategy for KIRC therapy.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31072238, 31172441, 31372562, 81170650, 81402105, 81402098, 81402087]; Chenguang Program of Wuhan Science and Technology Bereau [2015070404010199]; National Major Scientific and Technological Special Project for Significant New Drugs Development [2012ZX09303018]; NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA148759]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA010815, R01CA148759] Funding Source: NIH RePORTER
第一作者单位：[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China[2]Institute of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
通讯作者：
推荐引用方式(GB/T 7714)：
xiao haibing,tang kun,liu peijun,et al.LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma[J].ONCOTARGET.2015,6(35):38005-38015.doi:10.18632/oncotarget.5357.
APA：
xiao,haibing,tang,kun,liu,peijun,chen,ke,hu,junhui...&huang,qihong.(2015).LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.ONCOTARGET,6,(35)
MLA：
xiao,haibing,et al."LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma".ONCOTARGET 6..35(2015):38005-38015
